PLANO, TX & BALTIMORE, MD, USA I March 25, 2025 I Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All ...

PARIS, France I March 25, 2025 I The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to ...

NEW YORK, NY, USA I March 24, 2025 I On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by ...

GUANGDONG, China and BAGSVAERD, Denmark I March 24, 2025 IThe United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) ...

NANTONG, China and MELBOURNE, Australia I March 24, 2025 I Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA ...

BEIJING, China I March 24, 2025 I SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for ...

SUZHOU, China I March 23, 2025 I CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer ...

U.S. IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) ...

COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52. Opthea considering impact of negative trial results under its Development Fund ...

SHANGHAI, China I March 23, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, ...

EAST HANOVER, NJ, USA I March 20, 2025 I Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) ...